Scholar Rock Holding Corporation (SRRK) 주식 분석

회사 개요

Scholar Rock Holding Corporation is a biopharmaceutical enterprise dedicated to enhancing the quality of life for pediatric and adult patients suffering from spinal muscular atrophy (SMA) as well as other rare, severe, and debilitating neuromuscular conditions. Operating within the healthcare sector and specifically the biotechnology industry, the company leverages a novel understanding of molecular mechanisms involving growth factor activation to develop targeted therapies for these specialized patient populations. The company currently maintains a market capitalization of $5.74B and employs a workforce of 289 individuals across its operational facilities. These valuation and scale metrics indicate that the market assigns significant weight to the company's pipeline potential, positioning it as a substantial entity within the niche biotechnology landscape despite the absence of reported annual revenue figures in the current fiscal period. The substantial market cap relative to the reported employee count suggests a high valuation per employee, which is characteristic of late-stage biotechnology firms where intellectual property and clinical trial progress often drive value more than immediate cash flow generation.

재무 건전성

The company reports a net income of $-377,939,008 for the trailing twelve months, while EBITDA stands at $-382,987,008, indicating that the gap between revenue and net income is negligible or non-existent, which reflects a cost structure where operating expenses heavily outweigh any reported gross revenue or where revenue recognition methods result in a 0.0% gross margin. The free cash flow is recorded at $-162,622,256, which signifies that the company is consuming cash to fund its research and development activities rather than generating excess liquidity for shareholder returns or debt repayment. All three margin metrics—the gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that typically indicates a company in a pre-revenue or early-stage commercialization phase where costs are incurred before significant sales revenue is recognized in the financial statements. In terms of liquidity and solvency, the company holds $367.56M in cash against $108.92M in debt, resulting in a debt-to-equity ratio of 44.37, which suggests a balance sheet that is currently leveraged but supported by a significant cash reserve that exceeds total liabilities. The current ratio is listed at 6.95, a high figure that indicates strong short-term liquidity and a robust ability to meet its short-term obligations with its available current assets. Furthermore, the return on equity is -123.1% and the return on assets is -54.7%, metrics that reveal that management effectiveness is currently measured by the preservation of capital and the strategic reinvestment of resources into the drug development pipeline rather than by generating immediate financial returns on the existing equity base.

밸류에이션 평가

Valuation multiples for Scholar Rock are distorted by the lack of positive earnings, with the P/E ratio (TTM) listed as N/A and a forward P/E of -23.30, implying that the market is pricing the stock based on future expectations rather than historical profitability or current earnings trajectory. The price-to-book ratio is 22.09, a figure that indicates the market is valuing the company at a significant premium over its tangible book value, reflecting the high intangible asset value associated with its drug candidates and intellectual property portfolio. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also presented as N/A and -14.32 respectively, suggesting that traditional revenue-based or earnings-based valuation models are not applicable in the conventional sense for this biotechnology firm at this stage of development. The stock's recent trading range spans from a 52-week low of $22.71 to a high of $51.62, meaning the current price sits somewhere within this volatility band, subject to the unique risks and rewards associated with biotechnology market sentiment. The beta value is 0.69, indicating that the stock price exhibits lower volatility relative to the broader market, behaving more conservatively than the average equity in the S&P 500 despite the inherent risks of the biotechnology sector.

Growth & Income

The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of growth rates between revenue and earnings in the traditional sense and indicating that the company is not yet in a mature growth phase where historical growth trajectories can be analyzed. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, which is recorded as 0.0%, confirming that the firm retains all available earnings to reinvest into its clinical trials and operational expansion rather than providing income to shareholders. This reinvestment strategy is standard for biotechnology companies in the development phase, where capital expenditure is prioritized to advance assets through clinical stages toward regulatory approval. Consequently, the overall growth and income profile is defined by capital appreciation potential rather than current yield, relying entirely on the successful progression of its neuromuscular disease therapies to eventually generate the revenue necessary to support a sustainable dividend or significant earnings growth in future periods.